Thanks to the many Sanofi contributors and our collaborators at Denali Therapeutics. Thanks also to the ALS community, Target ALS, the The National Institutes of Health NeuroBioBank, and Mass General Hospital for providing the precious samples that made this study possible.
We hope this work furthers our understanding of the role neuroinflammatory pathways and reactive glia play in ALS and can help identify new targets for biomarker and therapeutic development for this devastating disease.
I'm pleased to share our most recent study led by Matija Zelic. We profiled human ALS spinal cords to uncover neuroinflammatory microglia and astrocyte states and show a key role for Ripk1 as a contributor to the pathological tissue environment in ALS.
www.cell.com/immunity/ful...
Thanks to the Sanofi R&D Digital team and to all who contributed to the development of the platform and the datasets in these studies.
2.) Microglia ferroptosis is regulated by SEC24B and contributes to neurodegeneration | Nature Neuroscience
3.) Glial state changes and neuroinflammatory RIPK1 signaling are a key feature of ALS pathogenesis | bioRxiv (in press)
Datasets from the following manuscripts authored by Matija Zelic, Sean Ryan, Greg Wirak, Dimitry Ofengeim, and many others are included
1.) BTK regulates microglial function and neuroinflammation in human stem cell models and mouse models of multiple sclerosis | Nature Communications
(cont)
I’m happy to share a free new resource to explore published single cell transcriptomic datasets from the Sanofi Rare and Neurologic Diseases Therapeutic Area.
talk2data.bioturing.com/sanofibrowser
